138 related articles for article (PubMed ID: 8726038)
1. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin.
Brouqui P; Badiaga S; Raoult D
Antimicrob Agents Chemother; 1996 Jun; 40(6):1552-4. PubMed ID: 8726038
[TBL] [Abstract][Full Text] [Related]
2. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.
Kersten A; Poitschek C; Rauch S; Aberer E
Antimicrob Agents Chemother; 1995 May; 39(5):1127-33. PubMed ID: 7625800
[TBL] [Abstract][Full Text] [Related]
3. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.
Preac Mursic V; Marget W; Busch U; Pleterski Rigler D; Hagl S
Infection; 1996; 24(1):9-16. PubMed ID: 8852456
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
Janovská D; Hulínská D; Godová T
Cent Eur J Public Health; 2001 Feb; 9(1):38-40. PubMed ID: 11243589
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.
Sicklinger M; Wienecke R; Neubert U
J Clin Microbiol; 2003 Apr; 41(4):1791-3. PubMed ID: 12682190
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
Baradaran-Dilmaghani R; Stanek G
Infection; 1996; 24(1):60-3. PubMed ID: 8852472
[TBL] [Abstract][Full Text] [Related]
7. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro.
Georgilis K; Peacocke M; Klempner MS
J Infect Dis; 1992 Aug; 166(2):440-4. PubMed ID: 1634816
[TBL] [Abstract][Full Text] [Related]
8. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
Dever LL; Jorgensen JH; Barbour AG
J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
[TBL] [Abstract][Full Text] [Related]
9. [Borrelia burgdorferi Group: in-vitro antibiotic sensitivity].
Henneberg JP; Neubert U
Orv Hetil; 2002 May; 143(21):1195-8. PubMed ID: 12073540
[TBL] [Abstract][Full Text] [Related]
10. Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.
Wu X; Sharma B; Niles S; O'Connor K; Schilling R; Matluck N; D'Onofrio A; Hu LT; Lewis K
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126963
[No Abstract] [Full Text] [Related]
11. In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.
Dever LL; Torigian CV; Barbour AG
Antimicrob Agents Chemother; 1999 Jul; 43(7):1773-5. PubMed ID: 10390242
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.
Johnson RC; Kodner CB; Jurkovich PJ; Collins JJ
Antimicrob Agents Chemother; 1990 Nov; 34(11):2133-6. PubMed ID: 2073103
[TBL] [Abstract][Full Text] [Related]
13. [Comment on Borrelia burgdorferi Group infections].
Bózsik BP
Orv Hetil; 2002 May; 143(21):1223-4. PubMed ID: 12073543
[No Abstract] [Full Text] [Related]
14. Antibiotics and increased temperature against Borrelia burgdorferi in vitro.
Reisinger E; Wendelin I; Gasser R; Halwachs G; Wilders-Truschnig M; Krejs G
Scand J Infect Dis; 1996; 28(2):155-7. PubMed ID: 8792482
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.
Johnson RC; Kodner C; Russell M
Antimicrob Agents Chemother; 1987 Feb; 31(2):164-7. PubMed ID: 3566246
[TBL] [Abstract][Full Text] [Related]
16. Forty Years of Evidence on the Efficacy and Safety of Oral and Injectable Antibiotics for Treating Lyme Disease of Adults and Children: A Network Meta-Analysis.
Yang J; Wen S; Kong J; Yue P; Cao W; Xu X; Zhang Y; Chen J; Liu M; Fan Y; Luo L; Chen T; Li L; Li B; Dong Y; Luo S; Zhou G; Liu A; Bao F
Microbiol Spectr; 2021 Dec; 9(3):e0076121. PubMed ID: 34756070
[TBL] [Abstract][Full Text] [Related]
17. Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro.
Varde S; Wormser GP; Nowakowski J; Nadelman RB; Bittker S; Cooper D; Schwartz I
Conn Med; 1999 Oct; 63(10):589-91. PubMed ID: 10578549
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi.
Yang X; Nguyen A; Qiu D; Luft BJ
J Antimicrob Chemother; 2009 Apr; 63(4):709-12. PubMed ID: 19182236
[TBL] [Abstract][Full Text] [Related]
19. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi.
Klempner MS; Noring R; Rogers RA
J Infect Dis; 1993 May; 167(5):1074-81. PubMed ID: 8486939
[TBL] [Abstract][Full Text] [Related]
20.
Koetsveld J; Draga ROP; Wagemakers A; Manger A; Oei A; Visser CE; Hovius JW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
